Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase
1997-10-15
Article
volume 80, issue 8 pp 1075-1077.
| Related Files |
|---|
View PDF Version
(9352981.pdf, 0.4MB) |
|
Redirect to publisher's version
(publisher's version.url.txt, 47 bytes) |
Peak serum C-reactive protein concentrations were measured in 146 patients randomized to receive streptokinase, alteplase, or a combination of streptokinase and alteplase in the GUSTO-I trial. Those receiving alteplase treatment had lower values than those receiving streptokinase or the combination treatment. Irrespective of treatment, complete reperfusion of the infarct-related artery (TIMI grade 3 flow) was associated with low peak serum C-reactive protein values.
Keywords
- Male
- Comparative Study
- Human
- Support, Non-U.S. Gov't
- Aged
- Female
- Middle Aged
- EC 3.4.- (Streptokinase)
- C-Reactive Protein/*metabolism
- Drug Therapy, Combination
- Streptokinase/*therapeutic use
- EC 1.1.1.30 (Hydroxybutyrate Dehydrogenase)
- EC 3.4.21.68 (Tissue Plasminogen Activator)
- Tissue Plasminogen Activator/*therapeutic use
- Myocardial Infarction/*blood/drug therapy
- 9007-41-4 (C-Reactive Protein)
- Hydroxybutyrate Dehydrogenase/*blood
Automatically Extracted Terms
- patient
- protein
- c-reactive
- serum
- treatment
- streptokinase
- grade
- value
- artery
- serum c-reactive protein
- infarct
- alteplase
- infarction
- group
- study
- infarct-related
- thrombolytic treatment
- thrombolytic
- simoons ml
- infarct-related artery
